{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T06:00:05Z","timestamp":1794031205969,"version":"4.8.0"},"reference-count":20,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,7]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>In this retrospective analysis of 584 patients who received chimeric antigen receptor T-cell therapy for large B-cell lymphoma at 6 Australian centers, no association was found between time of infusion and outcome, accounting for confounders, suggesting minimal clinical impact of chronobiology in this setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025032307","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T22:03:56Z","timestamp":1771365836000},"page":"2272-2277","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8056-5348","authenticated-orcid":false,"given":"Mark R.","family":"Dowling","sequence":"first","affiliation":[{"name":"1Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia"},{"name":"2The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia"},{"name":"3Centre of Excellence in Cellular Immunotherapy, Peter MacCallum Cancer Centre, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5977-907X","authenticated-orcid":false,"given":"Edward R. Scheffer","family":"Cliff","sequence":"additional","affiliation":[{"name":"1Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia"},{"name":"2The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4277-7478","authenticated-orcid":false,"given":"Anthony","family":"Jeffrey","sequence":"additional","affiliation":[{"name":"4Department of Haematology, Royal Prince Alfred Hospital, Camperdown, Australia"},{"name":"5Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catelyn","family":"Cashion","sequence":"additional","affiliation":[{"name":"6Blood Transplant and Cell Therapies Program, Department of Haematology, Westmead Hospital, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3138-4815","authenticated-orcid":false,"given":"Stephen","family":"Boyle","sequence":"additional","affiliation":[{"name":"7Cancer Care Services, Royal Brisbane and Women's Hospital, Metro North Hospital and Health Service, Brisbane, Australia"},{"name":"8Translational Cancer Immunotherapy Laboratory, QIMR Berghofer, Brisbane, Australia"},{"name":"9Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[{"name":"10Malignant Haematology, Transplantation and Cellular Therapy Service, Alfred Hospital, Melbourne, Australia"},{"name":"11Australian Centre for Blood Diseases, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Buss","sequence":"additional","affiliation":[{"name":"12Department of Haematology, Fiona Stanley Hospital, Murdoch, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"MacDonald","sequence":"additional","affiliation":[{"name":"7Cancer Care Services, Royal Brisbane and Women's Hospital, Metro North Hospital and Health Service, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Edelkina","sequence":"additional","affiliation":[{"name":"3Centre of Excellence in Cellular Immunotherapy, Peter MacCallum Cancer Centre, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4953-7815","authenticated-orcid":false,"given":"Hamish W.","family":"Scott","sequence":"additional","affiliation":[{"name":"1Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia"},{"name":"2The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole L.","family":"O\u2019Leary","sequence":"additional","affiliation":[{"name":"1Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1585-4234","authenticated-orcid":false,"given":"Michelle W.","family":"Keir","sequence":"additional","affiliation":[{"name":"4Department of Haematology, Royal Prince Alfred Hospital, Camperdown, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safia","family":"Belbachir","sequence":"additional","affiliation":[{"name":"12Department of Haematology, Fiona Stanley Hospital, Murdoch, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Westerman","sequence":"additional","affiliation":[{"name":"1Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia"},{"name":"13Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine S.","family":"Tam","sequence":"additional","affiliation":[{"name":"10Malignant Haematology, Transplantation and Cellular Therapy Service, Alfred Hospital, Melbourne, Australia"},{"name":"11Australian Centre for Blood Diseases, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2811-8671","authenticated-orcid":false,"given":"P. Joy","family":"Ho","sequence":"additional","affiliation":[{"name":"4Department of Haematology, Royal Prince Alfred Hospital, Camperdown, Australia"},{"name":"5Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4555-6582","authenticated-orcid":false,"given":"Simon J.","family":"Harrison","sequence":"additional","affiliation":[{"name":"1Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia"},{"name":"2The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia"},{"name":"3Centre of Excellence in Cellular Immunotherapy, Peter MacCallum Cancer Centre, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1615-0540","authenticated-orcid":false,"given":"Allison","family":"Barraclough","sequence":"additional","affiliation":[{"name":"12Department of Haematology, Fiona Stanley Hospital, Murdoch, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shafqat","family":"Inam","sequence":"additional","affiliation":[{"name":"10Malignant Haematology, Transplantation and Cellular Therapy Service, Alfred Hospital, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7849-7139","authenticated-orcid":false,"given":"Emily","family":"Blyth","sequence":"additional","affiliation":[{"name":"5Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia"},{"name":"6Blood Transplant and Cell Therapies Program, Department of Haematology, Westmead Hospital, Sydney, Australia"},{"name":"14Centre for Cancer Research, Westmead Institute for Medical Research, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2261-169X","authenticated-orcid":false,"given":"Andrea S.","family":"Henden","sequence":"additional","affiliation":[{"name":"7Cancer Care Services, Royal Brisbane and Women's Hospital, Metro North Hospital and Health Service, Brisbane, Australia"},{"name":"8Translational Cancer Immunotherapy Laboratory, QIMR Berghofer, Brisbane, Australia"},{"name":"9Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Vanguru","sequence":"additional","affiliation":[{"name":"4Department of Haematology, Royal Prince Alfred Hospital, Camperdown, Australia"},{"name":"5Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1492-5966","authenticated-orcid":false,"given":"Michael J.","family":"Dickinson","sequence":"additional","affiliation":[{"name":"1Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia"},{"name":"2The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia"},{"name":"3Centre of Excellence in Cellular Immunotherapy, Peter MacCallum Cancer Centre, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"12","key":"2026050711215554100_bib1","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/S1470-2045(21)00546-5","article-title":"Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study","volume":"22","author":"Qian","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026050711215554100_bib2","doi-asserted-by":"crossref","first-page":"105607","DOI":"10.1016\/j.ebiom.2025.105607","article-title":"Overall survival according to time-of-day of combined immuno-chemotherapy for advanced non-small cell lung cancer: a bicentric bicontinental study","volume":"113","author":"Huang","year":"2025","journal-title":"EBioMedicine"},{"key":"2026050711215554100_bib3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2023.01.007","article-title":"Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer","volume":"182","author":"Rousseau","year":"2023","journal-title":"Eur J Cancer"},{"issue":"5","key":"2026050711215554100_bib4","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.clgc.2023.06.004","article-title":"Association between time-of-day of immune checkpoint blockade administration and outcomes in metastatic renal cell carcinoma","volume":"21","author":"Dizman","year":"2023","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"2026050711215554100_bib5","doi-asserted-by":"crossref","first-page":"102220","DOI":"10.1016\/j.esmoop.2023.102220","article-title":"Effect of immunotherapy-infusion time of day on survival of patients with advanced cancers: a study-level meta-analysis","volume":"9","author":"Landr\u00e9","year":"2024","journal-title":"ESMO Open"},{"key":"2026050711215554100_bib6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04181-w","article-title":"Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial","author":"Huang","year":"2  2026","journal-title":"Nat Med"},{"issue":"2","key":"2026050711215554100_bib7","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.immuni.2014.02.002","article-title":"Circadian clock proteins and immunity","volume":"40","author":"Curtis","year":"2014","journal-title":"Immunity"},{"issue":"7","key":"2026050711215554100_bib8","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/s41590-024-01859-0","article-title":"Circadian control of tumor immunosuppression affects efficacy of immune checkpoint blockade","volume":"25","author":"Fortin","year":"2024","journal-title":"Nat Immunol"},{"issue":"11","key":"2026050711215554100_bib9","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1016\/j.cell.2024.04.015","article-title":"Circadian tumor infiltration and function of CD8+ T cells dictate immunotherapy efficacy","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"issue":"19","key":"2026050711215554100_bib10","first-page":"2307","article-title":"5-Year follow-up supports curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1)","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"issue":"16","key":"2026050711215554100_bib11","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2026050711215554100_bib12","doi-asserted-by":"crossref","first-page":"e201159","DOI":"10.1172\/jci.insight.201159","article-title":"Diurnal rhythm in chimeric antigen receptor T-cell effectiveness in an observational study of 715 patients","volume":"11","author":"Lyons","year":"2025","journal-title":"JCI Insight"},{"issue":"12","key":"2026050711215554100_bib13","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1182\/blood.2025031476","article-title":"Time of day of CAR T-Cell infusion and outcomes in large B-cell lymphoma","volume":"147","author":"Luan","year":"2026","journal-title":"Blood"},{"issue":"10","key":"2026050711215554100_bib14","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","article-title":"A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat Med"},{"issue":"suppl 1","key":"2026050711215554100_bib15","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1182\/blood-2023-186510","article-title":"Impact of sex on clinical outcomes after CD19 CAR T-cell therapy for large B-cell lymphoma: response and survival are significantly superior in female compared to male patients [abstract]","volume":"142","author":"Buecklein","year":"2023","journal-title":"Blood"},{"issue":"19","key":"2026050711215554100_bib16","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"2026050711215554100_bib17","first-page":"581.e1.581.e8","article-title":"Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"2026050711215554100_bib18","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"2026050711215554100_bib19","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1182\/bloodadvances.2022009019","article-title":"Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma","volume":"7","author":"Roddie","year":"2023","journal-title":"Blood Adv"},{"key":"2026050711215554100_bib20","first-page":"2025.05.15.25327612","article-title":"Diurnal rhythms in chimeric antigen receptor T cell performance: an observational study of 670 patients","author":"Lyons","year":"16  2025","journal-title":"medRxiv"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/19\/2272\/2517416\/blood_bld-2025-032307-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/19\/2272\/2517416\/blood_bld-2025-032307-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T15:22:06Z","timestamp":1778167326000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/19\/2272\/566631\/Time-of-infusion-does-not-significantly-impact"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":20,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026,5,7]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025032307","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,7]]},"published":{"date-parts":[[2026,5,7]]}}}